{
  "resourceType": "ValueSet",
  "id": "shr-oncology-NottinghamComponentNullVS",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<p><b>BC NottinghamComponentNullVS ValueSet</b></p>\n<p>Data absent reasons (null values) for nuclear pleomorphism count and tubule formation score. Aligns with LOINC normative answer lists LL4382-9 and LL4380-3.</p>\n</div>"
  },
  "url": "http://hl7.org/fhir/us/breastcancer/ValueSet/shr-oncology-NottinghamComponentNullVS",
  "identifier": [
    {
      "system": "http://hl7.org/fhir/us/breastcancer",
      "value": "shr.oncology.NottinghamComponentNullVS"
    }
  ],
  "name": "NottinghamComponentNullVS",
  "title": "BC NottinghamComponentNullVS ValueSet",
  "status": "draft",
  "publisher": "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)",
  "contact": [
    {
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/cic/index.cfm"
        }
      ]
    }
  ],
  "date": "2018-08-13",
  "description": "Data absent reasons (null values) for nuclear pleomorphism count and tubule formation score. Aligns with LOINC normative answer lists LL4382-9 and LL4380-3.",
  "compose": {
    "include": [
      {
        "system": "http://loinc.org",
        "concept": [
          {
            "code": "LA27219-7",
            "display": "Only microinvasion present (not graded)"
          },
          {
            "code": "LA27220-5",
            "display": "No residual invasive carcinoma after presurgical (neoadjuvant) therapy"
          },
          {
            "code": "LA27221-3",
            "display": "Score cannot be determined"
          }
        ]
      }
    ]
  }
}